Boston Scientific has struck a deal to buy medical-device maker Silk Road Medical for about $1.26 billion, adding a technology for stroke prevention to its vascular portfolio.

Boston Scientific is up 10.7% since the beginning of the year, and at $98.92 per share, it is trading close to its 52-week high of $106.18 from February 2025.

The Boston Globe Its stock is up 50 percent. Billion-dollar deals for breakfast. How did Boston Scientific get its mojo back? “It’s been a brick by brick, constant improvement, strengthening ...

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.

Boston Scientific (BSX) ended the recent trading session at $90.53, demonstrating a -0.34% swing from the preceding day's closing price. This change lagged the S&P 500's 0.19% loss on the day ...

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ...

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.

Medical-products company Boston Scientific reported third-quarter results before market open Last Updated: Oct. 23, 2024 at 7:39 a.m. ET First Published: Oct. 23, 2024 at 6:55 a.m. ET Share ...

Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.

With the acquisition, Boston Scientific will pay $360 million upfront for the remaining 90% stake and up to an additional $180 million once specific regulatory milestones are met.